CNS Summit 2014, Boca Raton, FL Ole Voges, Ingo Weigmann, Norman Bitterlich, Christoph Schindler and Christopher Missling View Poster Post navigationPreviousPrevious post:Anavex Announces Positive Phase 1 Data for ANAVEX 2-73, Lead Candidate for the Treatment of Alzheimer’sNextNext post:Anavex Upgrades to OTCQX MarketplaceRelated PostsAnavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program UpdatesDecember 28, 2020Anavex Life Sciences to Announce Fiscal 2020 Year End Financial Results December 28th, 2020December 22, 2020Anavex Life Sciences Announces Webinar on Rett Syndrome and ANAVEX®2-73 (Blarcamesine) Phase 2 Data hosted by Ladenburg Thalmann & Co.December 21, 2020Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Meets Primary and Secondary Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett SyndromeDecember 15, 2020
Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program UpdatesDecember 28, 2020
Anavex Life Sciences to Announce Fiscal 2020 Year End Financial Results December 28th, 2020December 22, 2020
Anavex Life Sciences Announces Webinar on Rett Syndrome and ANAVEX®2-73 (Blarcamesine) Phase 2 Data hosted by Ladenburg Thalmann & Co.December 21, 2020
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Meets Primary and Secondary Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett SyndromeDecember 15, 2020
